Full Text Journal Articles by
Author Theodoros Alexopoulos


Find full text journal articles

Letter: patients who have both sarcopenia and frailty have similar prognosis to those with either condition separately.

Theodoros Alexopoulos, Larisa Vasilieva, Meropi D Kontogianni, Iliana Mani, Alexandra Alexopoulou,

Aliment Pharmacol Ther (Alimentary pharmacology & therapeutics)
[2021, 54(7):981-982]

Cited: 0 times

View full text PDF listing >>

Myostatin in combination with creatine phosphokinase or albumin may differentiate patients with cirrhosis and sarcopenia.

Theodoros Alexopoulos, Larisa Vasilieva, Meropi D Kontogianni, Roxane Tenta, Alexandra Georgiou, Evangelia Stroumpouli, Iliana Mani, Alexandra Alexopoulou,

<h4>Background/objectives</h4>In patients with liver cirrhosis (LC), sarcopenia is correlated with frequent complications and increased mortality. Myostatin-a myokine-is a potential biomarker of skeletal mass and/or sarcopenia. The aim of this study was to examine the association between myostatin and muscle-mass and evaluate myostatin as a biomarker of sarcopenia in LC.<h4>Methods</h4>Skeletal-muscle-index (SMI) ... Read more >>

Am J Physiol Gastrointest Liver Physiol (American journal of physiology. Gastrointestinal and liver physiology)
[2021, :]

Cited: 0 times

View full text PDF listing >>


Evaluation of noninvasive markers for the diagnosis of cystic fibrosis liver disease.

Alexandra Alexopoulou, Sophia Pouriki, Larisa Vasilieva, Theodoros Alexopoulos, Vasiliki Filaditaki, Maria Gioka, Filia Diamantea, Spyros P Dourakis,

<h4>Objectives</h4>In cystic fibrosis (CF), liver disease (LD) is the third leading cause of mortality. As liver biopsy was considered inconsistent in CFLD diagnosis, a combination of modalities were utilized in the conventional Debray criteria (DC). More recently, noninvasive liver fibrosis biomarkers were applied by Koh et al (New criteria-NC). In the ... Read more >>

Scand J Gastroenterol (Scandinavian journal of gastroenterology)
[2018, 53(12):1547-1552]

Cited: 2 times

View full text PDF listing >>

Human beta-defensin-1 is a highly predictive marker of mortality in patients with acute-on-chronic liver failure.

Iliana Mani, Alexandra Alexopoulou, Larisa Vasilieva, Emilia Hadziyannis, Danai Agiasotelli, Myrianthi Bei, Theodoros Alexopoulos, Spyros P Dourakis,

<h4>Background & aim</h4>Human beta-defensin-1 (hBD-1) is a natural antimicrobial peptide expressed in the epithelia of multiple tissues including the digestive tract. In the current study, hBD-1 levels were determined in different subsets of patients with decompensated cirrhosis including acute-on-chronic liver failure (ACLF). In addition, the association with mortality of hBD-1, ... Read more >>

Liver Int (Liver international : official journal of the International Association for the Study of the Liver)
[2019, 39(2):299-306]

Cited: 1 time

View full text PDF listing >>



1.5637 s